The Effect of a Cardiovascular Polypill Strategy on Pill Burden

Cardiovascular Therapeutics

Volumn 33, Issue 6, 2015, Pages 347-352

  Truelove, Michael ^a   Patel, Anushka ^b   Bompoint, Severine ^b   Brown, Alex ^c   Cass, Alan ^d   Hillis, Graham S ^e   Peiris, David ^b   Rafter, Natasha ^f   Reid, Christopher M ^g,h   Rodgers, Anthony ^b   Tonkin, Andrew ^g   Usherwood, Tim ^a   Webster, Ruth ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^g MONASH UNIVERSITY   (Australia)

^h CURTIN UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Polypill; Prescribing; Preventive medicine; Primary care

Indexed keywords

ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS LISINOPRIL PLUS SIMVASTATIN; ACETYLSALICYLIC ACID PLUS HYDROCHLOROTHIAZIDE PLUS LISINOPRIL PLUS SIMVASTATIN; AMLODIPINE; ATENOLOL; ATORVASTATIN; CARDIOVASCULAR AGENT; CHOLESTEROL; FLUINDOSTATIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; METOPROLOL; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TABLET;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHYSICIAN; PILL; PILL BURDEN; POLYPILL; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; TABLET; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TABLETS; TREATMENT OUTCOME;

EID: 84945972329     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12151     Document Type: Article

References (19)

1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Sundstrom J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591-598.
3. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet 2015;385:1397-1405.
4. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243.
5. Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009;191:324-329.
6. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254-259.
7. Peiris DP, Patel AA, Cass A, et al. Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: findings from the Kanyini Audit. Med J Aust 2009;191:304-309.
8. Miller NH, Hill M, Kottke T, Ockene IS. For the expert panel on compliance. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation 1997;95:1085-1090.
9. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004;292:952-960.
10. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010;44:1410-1421.
11. George J, Elliott RA, Stewart DC. A systematic review of interventions to improve medication taking in elderly patients prescribed multiple medications. Drugs Aging 2008;25:307-324.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
13. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2014;22:920-930.
14. Liu H, Patel A, Brown A, et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health 2010;10:458.
15. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(Pt 2):293-298.
16. New Zealand Guidelines Group. Assessment and management of cardiovascular risk. Wellington: New Zealand Guidelines Group, 2003.
17. Hung J, on behalf of the National Heart Foundation of Australia. Position statement - aspirin for cardiovascular disease prevention. Med J Aust 2003;179:147-152.
18. Pharmaceutical Benefits Scheme (AU) [Internet]. Department of Health, Australian Government [Cited 13 May 2015]. Available from: http://www.pbs.gov.au/pbs/home.
19. Laba TL, Hayes A, Lo S, et al. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Med J Aust 2014;201:671-673.